A Multicenter Cohort Study of HPV Viral Load in Predicting the Postoperative Recurrence of HSIL
NCT ID: NCT05282745
Last Updated: 2023-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4000 participants
OBSERVATIONAL
2021-12-15
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prognostic Study of HPV Virus Integration in Women With HSIL
NCT05745597
HPV Viral Load in Predicting the Prognosis of LSIL
NCT05051852
Research About Impact of HPV Integration on the Prognosis of Women With Persistent HR-HPV Infection
NCT05283239
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
NCT05282095
The Predictive Role of HPV Integration in HSIL and Cervical Cancer
NCT05300243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Women with high-grade squamous intraepithelial lesion (HSIL) in cervix
In the enrollment, women whose cervical histopathological results have been diagnosed as high-grade squamous intraepithelial lesion (HSIL) for the last 3 months with abnormal results will be included in this study. All participants will be followed up three times, at 6 months,12 months and 24 months.
Follow-up
Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Follow-up
Participants will be followed up at 6, 12 and 24 months with HPV viral load tests, Thinprep cytologic tests (TCT) and vaginal secretion tests.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The result of cervical histopathology in the last 3 months was high-grade squamous intraepithelial lesion (HSIL).
* Non pregnant people with sexual history.
* Asexual life, no vaginal medication or flushing before 72 hours of sampling.
Exclusion Criteria
* Patients with history of genital tract tumor.
* History of HPV vaccination.
* Previous history of hysterectomy, cervical surgery, pelvic radiotherapy Historical.
* In recent one month, she has received genital tract infection, HPV or other STDs treatment related to the infection of mycoplasma.
* Use antibiotics or vaginal microecological improvement products in recent 1 month.
20 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fujian Maternity and Child Health Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Binhua Dong
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pengming Sun, PhD
Role: STUDY_CHAIR
Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fujian Maternity and Child Health Hospital
Fuzhou, Fujian, China
Mindong Hospital of Ningde City
Ningde, Fujian, China
Ningde Municipal Hospital of Ningde Normal University
Ningde, Fujian, China
The First Hospital of Putian City
Putian, Fujian, China
Quanzhou First Hospital Afflicated to Fujian Medical University
Quanzhou, Fujian, China
Zhangzhou affiliated Hospital of Fujian Medical University
Zhangzhou, Fujian, China
Longyan First Hospital
Longyan, , China
Shenzhen Maternity and child Healthcare Hospital
Shenzhen, , China
Maternity and child Hospital of Hubei Province
Wuhan, , China
Xiamen Maternity and Child Health Hospital
Xiamen, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Fang Xie, M.D
Role: primary
Wenfang Jin
Role: primary
Xianqian Chen
Role: primary
Yuchun' Lv, M.D
Role: primary
Feifeng Shi, M.D
Role: primary
Jinyong Wang
Role: primary
Zheng Zheng
Role: primary
Hongning Cai
Role: primary
Qing Li
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PVLHCF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.